Breaking Down Ypsomed Holding AG Financial Health: Key Insights for Investors

Investors tracking Ypsomed Holding AG will want to dig into results that show a striking top-line surge-revenue up 36.54% to CHF 748.87 million for the year to March 31, 2025 and a trailing twelve months figure of CHF 787.55 million (+27.63% YoY)-driven by a resilient core Delivery Systems business reporting CHF 267 million in H1 2025/26 sales (a 21% increase), underpinning analyst expectations of ~20% full-year Delivery Systems growth and an EBIT range of CHF 190-210 million; operational strength is reflected in a robust EBIT margin of 32.4% in Delivery Systems and H1 net profit of CHF 139.1 million (EPS CHF 10.19), while cash generation (operating cash flow >CHF 140 million for the core business and free cash flow ~CHF 288 million aided by the CHF 307 million Diabetes Care disposal) has fortified the balance sheet to equity of CHF 807.2 million and an equity ratio of 66.8% as of Sept 30, 2025, with net financial liabilities trimmed to CHF 73.7 million and net debt/EBITDA down to 0.3×-factors that support capacity expansion plans (targeting 1 billion devices by decade-end and >CHF 100 million in investment through 2030) even as valuation and risk dynamics warrant scrutiny (P/E at 62.7× vs. the European Medical Equipment average of 33.8×, a consensus 12‑month price target of CHF 406.11 implying ~29.5% upside, offset by near-term headwinds such as a CHF 20-30 million sales reduction from contract manufacturing phaseout, a beta >1 and the impacts of the Diabetes Care divestiture), and analysts nonetheless forecast a 32.6% annual earnings growth trajectory with ROE rebounding to 19.8% by 2028-read on for a line-by-line breakdown of the numbers, risks and upside.

Ypsomed Holding AG (0QLQ.L) - Revenue Analysis

Ypsomed Holding AG reported robust top-line expansion across FY 2024/25 and into 2025/26, driven primarily by its Delivery Systems business and stronger-than-industry demand for medical devices and wearable delivery platforms. Key figures and trends are summarized below.

• FY ending 31 Mar 2025 revenue: CHF 748.87 million (up 36.54% vs CHF 548.46 million in FY 2023/24).
• Trailing twelve months (TTM) revenue as of Sep 2025: CHF 787.55 million - +27.63% YoY.
• 1H 2025/26 total sales: CHF 363 million; Delivery Systems sales: CHF 267 million (up 21% YoY in the segment).
• Analyst expectations for full FY Delivery Systems growth: ~20%; projected EBIT range: CHF 190-210 million.
• Revenue growth vs Swiss Medical Equipment industry forecast (7.6%): significantly outpaced the sector.

Drivers behind the revenue acceleration include expanding Delivery Systems orders, higher recurring sales from device platforms, and market share gains versus the broader Swiss medical equipment growth rate. For context on Ypsomed's broader strategy and corporate background, see Ypsomed Holding AG: History, Ownership, Mission, How It Works & Makes Money.

Ypsomed Holding AG (0QLQ.L) - Profitability Metrics

• EBIT margin (Delivery Systems, H1 2025/26): 32.4% - indicating high operational efficiency in the core devices business.
• Net profit (H1 2025/26): CHF 139.1 million, with EPS: CHF 10.19 - a strong half-year earnings result.
• Gross margin (FY ended 31 Mar 2025): 39.0% - healthy product-level profitability.
• Operating cash flow (core business): > CHF 140 million - solid cash generation from operations.
• Free cash flow (including divestitures): ~ CHF 288 million - materially boosted by sales of non-core assets.
• ROE (2025): 0% - driven by one-time effects from the sale of the Diabetes Care segment and restructuring charges; a temporary distortion of return metrics.
• Analyst forecast (ROE 2028): 19.8% - reflecting expected normalization and earnings recovery.
• Analyst-projected earnings growth: 32.6% annual increase in EPS (projected to drive the ROE rebound).

• Implication: high margins and cash flow from the Delivery Systems core business underpin intrinsic profitability, while ROE and headline ratios for 2025 are distorted by strategic divestitures and restructuring; consensus forecasts imply a sharp normalization through 2028.
• Risk/Watchlist: sustaining segment margins, redeploying divestiture proceeds effectively, and delivering on the projected earnings growth to realize the forecast ROE improvement.

Ypsomed Holding AG (0QLQ.L) - Debt vs. Equity Structure

• Equity: CHF 807.2 million (equity ratio 66.8%, up from 51.1% a year earlier)
• Net financial liabilities: CHF 73.7 million (down from CHF 272.9 million)
• Net debt / EBITDA (LTM): 0.3× (previous year: 1.4×)
• One-off cash inflow from sale: CHF 307.0 million (H1 2025/26)

• Improved liquidity: CHF 307m proceeds materially increased cash and reduced leverage.
• Stronger solvency: equity ratio at 66.8% provides a conservative capital base.
• Lower leverage: net debt/EBITDA of 0.3× supports investment without external financing.
• Financial flexibility: reduced net financial liabilities create headroom for capex and organic growth.

Ypsomed Holding AG (0QLQ.L) - Liquidity and Solvency

Ypsomed's balance sheet and cash-flow performance through the first half of 2025/26 show marked improvement in both liquidity and solvency metrics, driven by operational cash generation and one-off portfolio actions.

• Operating cash flow (core business, H1 2025/26): > CHF 140 million.
• Free cash flow (H1 2025/26): ~ CHF 288 million (bolstered by the sale of the Diabetes Care segment).
• Equity ratio (30 Sep 2025): 66.8% (previous year: 51.1%).
• Net debt / EBITDA: 0.3× (previous: 1.4×), reflecting materially lower leverage.
• Strong liquidity supports capacity expansion and strategic initiatives.
• Improved financial resilience provides a buffer against market and operational volatility.

Key implications for investors:

• High operating cash conversion in the core business suggests sustainable core earnings quality.
• One-off proceeds significantly strengthened free cash flow and allowed rapid deleveraging.
• A 66.8% equity ratio indicates conservative capital structure and increased financial flexibility.
• Net debt/EBITDA of 0.3× provides headroom for continued capital expenditure on capacity expansion and funding strategic initiatives with limited refinancing risk.

Further background and investor context can be found here: Exploring Ypsomed Holding AG Investor Profile: Who's Buying and Why?

Ypsomed Holding AG (0QLQ.L) - Valuation Analysis

• High P/E (62.7×) - more than double the industry average (33.8×), indicating the market prices significant growth into the stock.
• Top-line momentum - TTM revenue CHF 787.55M with 27.63% YoY growth supports growth narrative behind valuation.
• Analyst projections - 20% growth in Delivery Systems and EBIT CHF 190-210M provide earnings trajectory to justify premium multiples if achieved.
• Price target vs. current price - CHF 406.11 consensus implies ~29.54% upside, reflecting continued confidence but also dependence on execution.

Ypsomed Holding AG (0QLQ.L) - Risk Factors

• Divestiture of the Diabetes Care segment: short-term revenue headwind but sharpened strategic focus on core medtech/pen systems.
• Phaseout of contract manufacturing: expected reduction in sales of CHF 20-30 million in the next fiscal year, creating a measurable near-term revenue gap.
• High equity volatility: stock beta > 1 (approx. 1.3), indicating greater sensitivity to market movements and macro risk.
• Valuation stretch: elevated P/E ratio (~35x) relative to peers, raising overvaluation concerns if growth slows.
• Operational execution risk: flat growth in the pen business signals need for product, pricing or commercial adjustments.
• Competitive & technological risk: intensified competition and rapid tech change in medical devices could pressure market share and margins.

• Cash-flow and liquidity sensitivity: the CHF 20-30m contract-manufacturing gap plus transitional costs from the Diabetes Care divestiture could compress free cash flow in the near term.
• Growth vs. valuation mismatch: with flat segments (pens) and elevated multiples, upside requires either accelerated organic growth or margin expansion.
• Execution dependence: realizing benefits of refocused strategy depends on successful commercialization, cost control, and retaining key manufacturing and development capabilities.
• External pressures: currency moves (CHF strength), reimbursement dynamics, and regulatory approvals directly affect revenue visibility.

Ypsomed Holding AG (0QLQ.L) - Growth Opportunities

• Manufacturing scale: target capacity of 1 billion devices by 2030 through new facilities in China, Germany and the U.S.
• Product innovation: commercial rollouts of YpsoDot, YpsoFlow and YpsoLoop to address insulin and biologic delivery needs.
• High-margin mix: emphasis on Delivery Systems (insulin pumps, pen injectors, smart devices) to lift gross margins and EBITDA.
• Geographic diversification: ~40% of sales derived from Asia‑Pacific, reducing concentration risk in European markets.
• Capital program: investment commitment exceeding CHF 100 million through 2030 aimed at automation, capacity and operational efficiency.
• Commercial catalysts: GLP‑1 partnerships and broader adoption of mylife YpsoPump underpin consensus-driven earnings acceleration.

• Execution levers: capacity growth (China/DE/US), manufacturing automation (CHF 100M+ spend), and commercial rollouts of YpsoDot/YpsoFlow/YpsoLoop.
• Revenue levers: expanded GLP‑1 and diabetes device partnerships, accelerated adoption of mylife YpsoPump, and higher ASPs from smart delivery platforms.
• Risk mitigants: diversified manufacturing footprint and sizable APAC revenue share reduce single‑market exposure; investment program targets unit‑cost decline and margin improvement.